Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include very common findings: Gait ataxia; and common findings: Gaze-evoked horizontal nystagmus, Diplopia, Shrinkage of the cerebellum (cerebellar atrophy), and Dysarthria and others. 9 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 4 | Dysarthria, Gait ataxia, Postural tremor |
FGF14 encodes fibroblast growth factor 14 (247 aa). Probably involved in nervous system development and function Highest expression in Brain Cerebellar Hemisphere (20.7 TPM) and Brain Cerebellum (16.5 TPM).
Spinocerebellar ataxia 27B, late-onset is associated with mutations in the FGF14 gene on chromosome 13.
FGF14 is classified as a druggable target (Clinically Actionable and Growth Factor categories) with score 0.9.
GAA-FGF14-related ataxia should be suspected in probands with the following clinical findings, imaging findings, and family history. Clinical findings. Mid to late adult-onset (median age: 60 years; range: 21 to 87 years) of slowly progressive cerebellar ataxia. Commonly associated neurologic findings include the following:
Source: GeneReviews — "GAA-FGF14-Related Ataxia"
No approved treatments are currently available for spinocerebellar ataxia 27B, late-onset. The disease remains an area of unmet medical need.
No clinical practice guidelines for GAA-FGF14-related ataxia have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To establish the extent of disease and needs in an individual diagnosed with GAA-FGF14-related ataxia, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended.
Table 6.
GAA-FGF14-Related Ataxia: Recommended Surveillance
System/Concern | Evaluation | Frequency
| • Neurologic eval to assess progression need for pharmacotherapy
No clinical trials have been registered for spinocerebellar ataxia 27B, late-onset.
32 publications have been identified in PubMed for spinocerebellar ataxia 27B, late-onset. Research spans Epidemiology / Natural History (31%), Case Report / Case Series (19%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 10 | 31% |
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 5:00 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Eyes
3 |
Gaze-evoked horizontal nystagmus, Diplopia, Downbeat nystagmus |
Ears | 1 | Vertigo |
Muscles | 1 | Shrinkage of the cerebellum (cerebellar atrophy) |
Bones and joints | 1 | Postural tremor |
Arms and legs | 1 | Limb ataxia |
To date, more than 400 individuals with GAA-FGF14-related ataxia have been identified [, , , , , , , , , , , , , , , ]. The following description of the phenotypic features associated with this condition is based on these reports . Table 2. GAA-FGF14-Related Ataxia: Frequency of Select Features
Feature | % of Persons w/Feature | Comment |
|---|---|---|
Gait | 95%-100% | — |
Upper limb | 44%-71% | — |
Episodic symptoms | 13%-80% | May be triggered by exercise/ physically demanding tasks, alcohol intake, or caffeine |
Cerebellar dysarthria | 12%-74% | — |
Cerebellar oculomotor signs | 80%-96% | Includes saccadic pursuit, dysmetric saccades, rebound nystagmus, gaze-evoked nystagmus, downbeat nystagmus, impaired visual fixation suppression of vestibuloocular reflex Nystagmus |
Horizontal gaze-evoked | 33%-67% | — |
Downbeat | 10%-67% | May be episodic; at disease onset may occur w/other cerebellar oculomotor signs in absence of other neurologic findings |
Diplopia, oscillopsia, visual blurring | 40%-68% | — |
Decreased vibration sense in distal lower extremities | 29%-57% | — |
Dysphagia | 14%-35% | — |
Vertigo or dizziness | 21%-67% | — |
Postural tremor of upper limbs | 10%-27% | — |
Vestibulopathy | 10%-75% | — |
Spasticity | 3%-21% | Generally mild GAA-FGF14-related ataxia is a mid to late adult-onset slowly progressive cerebellar syndrome with predominant gait involvement. Age of onset and clinical presentation can vary within the same family. The median age at onset is 60 years (range: 21 to 87 years) [, , , , , , ]. |
Source: GeneReviews — "GAA-FGF14-Related Ataxia"
Reduced penetrance has been reported in persons heterozygous for 250-300 FGF14 GAA repeats . It is likely that knowledge of GAA repeat length-related penetrance will evolve significantly as more data become available.
Source: GeneReviews — "GAA-FGF14-Related Ataxia"
GAA-FGF14-related ataxia has been reported in persons of multiple ancestral backgrounds and is among the most common causes of hereditary – in particular autosomal dominant – adult-onset ataxia [, , , , ]. In a single-center study, GAA-FGF14-related ataxia accounted for 16% of German individuals with autosomal dominant cerebellar ataxia . The differential diagnosis of adult-onset ataxia is broad and encompasses acquired, hereditary, and neurodegenerative ataxias. Hereditary adult-onset ataxias. The clinical features of GAA-FGF14-related ataxia, including oculomotor signs, are similar to those of other hereditary pure cerebellar ataxias, such as spinocerebellar ataxia type 6 (SCA6) and SCA8.
Source: GeneReviews — "GAA-FGF14-Related Ataxia"
Genetic testing for FGF14 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for spinocerebellar ataxia 27B, late-onset has been reported in the published literature.
Table 4.
GAA-FGF14-Related Ataxia: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Neurologic assessment for cerebellar motor dysfunction (gait postural ataxia, dysmetria, dysdiadochokinesis, tremor, dysarthria, nystagmus, saccades, smooth pursuit) | Use clinical neurologic eval standardized scale to establish baseline for ataxia, such as SARA.1
Assessment for non-ataxia signs (reflexes, motor symptoms, tone, tremor, sensory symptoms, dysphagia, urinary dysfunction, cognitive impairment) | Use clinical neurologic eval standardized scale to establish baseline for non-ataxia involvement, such as INAS.2
Nerve conduction studies | Establish presence severity of sensory or sensorimotor peripheral neuropathy.
Vestibulopathy | Vestibular testing (video head impulse test) to assess vestibular hypofunction
Clinical assessment of symptoms of autonomic dysfunction | • Assess for postural change in blood pressure to assess for orthostatic hypotension.
Source: GeneReviews — "GAA-FGF14-Related Ataxia"
View trials for spinocerebellar ataxia 27B, late-onset
Monitor ataxia progression w/standardized scale (SARA).1
| Annually; more often for acute exacerbation
PT eval re mobility, need for durable equipment | Per treating PT
OT eval re ADL, need for safety modifications | Per treating OT
| Eval re need for speech therapy or alternative communication method | Per symptom progression
| Assessment of nutrition, aspiration risk, feeding methods
| Eval by ophthalmologist for prisms
| Eval by audiologist for hearing aids
| Assess family need for social work support, care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning). | At each visit
OT = occupational therapy/therapist; PT = physical therapy/therapist; SARA = Scale for the Assessment and Rating of Ataxia
1.
Source: GeneReviews — "GAA-FGF14-Related Ataxia"
Phenotype severity distribution: 1 very common feature, 5 common features.
Patient case studies
6 |
19% |
Research summaries | 5 | 16% |
Testing and diagnosis research | 4 | 13% |
Laboratory research | 4 | 13% |
Other research | 2 | 6% |
Clinical study results | 1 | 3% |
Avila A (2026). [PMID: 42142446](https://pubmed.ncbi.nlm.nih.gov/42142446/). *J Neurol Sci*. [Other]
Gold DR (2026). [PMID: 40693779](https://pubmed.ncbi.nlm.nih.gov/40693779/). *J Neuroophthalmol*. [Basic Science / Preclinical]
Yomtoob J (2026). [PMID: 41698164](https://pubmed.ncbi.nlm.nih.gov/41698164/). *Neurology*. [Case Report / Case Series]
Unknown (2026). [PMID: 41700957](https://pubmed.ncbi.nlm.nih.gov/41700957/). *J Neuroophthalmol*. [Review / Meta-Analysis]
Skacik P (2026). [PMID: 42113379](https://pubmed.ncbi.nlm.nih.gov/42113379/). *Doc Ophthalmol*. [Case Report / Case Series]
Pons NC (2026). [PMID: 42090775](https://pubmed.ncbi.nlm.nih.gov/42090775/). *J Neurol Sci*. [Diagnostic / Biomarker]
Matlawska M (2026). [PMID: 42096001](https://pubmed.ncbi.nlm.nih.gov/42096001/). *Cerebellum*. [Epidemiology / Natural History]
Matovu D (2026). [PMID: 42155556](https://pubmed.ncbi.nlm.nih.gov/42155556/). *J Neurol Sci*. [Other]
de Jesus Araujo Dias A (2026). [PMID: 42168446](https://pubmed.ncbi.nlm.nih.gov/42168446/). *J Neurol*. [Epidemiology / Natural History]
Hirschfeld AS (2025). [PMID: 40299270](https://pubmed.ncbi.nlm.nih.gov/40299270/). *J Appl Genet*. [Review / Meta-Analysis]